Scarica l'app Stockscreener
12.30
2.15%
-0.27
Precedente Chiudi:
$12.57
Aprire:
$12.56
Volume 24 ore:
1,762
Relative Volume:
0.51
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.23%
1M Prestazione:
+1.49%
6M Prestazione:
-18.27%
1 anno Prestazione:
-22.40%
Intervallo 1D:
$12.30
$12.59
Intervallo di 1 settimana:
$12.30
$13.00
Portata 52W:
$11.38
$17.96
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Nome
Range Cancer Therapeutics Etf
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CNCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
12.30 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
295.92 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
599.94 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
602.87 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
239.61 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
526.08 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf Borsa (CNCR) Ultime notizie
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
This Warren Buffett Index Fund Could Turn $400 Per Month Into $868,200 - The Globe and Mail
Psychedelic ETF PSIL Is 2025's Best-Performing ETF - etf.com
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter
7 Best-Performing Biotech ETFs for February 2025 - NerdWallet
When (CNCR) Moves Investors should Listen - Stock Traders Daily
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
Reston Hospital Center adds inpatient unit to expand its range of oncology services - Yahoo Finance
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Looking for Gold Exposure in 2025? 3 ETFs to Consider - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
(CNCR) Investment Analysis - Stock Traders Daily
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer (LPTX) - Seeking Alpha
Total World Stock Index ETF Vanguard (VT-A) QuotePress Release - The Globe and Mail
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Texas Instruments (TXN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Science & Technology | TBR News Media | Page 2 - TBR News Media
Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR - GlobeNewswire Inc.
(CNCR) Trading Report - Stock Traders Daily
Enbridge Inc (ENB-N) QuotePress Release - The Globe and Mail
Cold Spring Harbor Laboratory - TBR News Media
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields (NVCR) - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds - MSN
Daniel Dunaief - TBR News Media
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Disruptive Theme of the Week: Breakthroughs in Medicine - ETF Trends
CSHL and Range ETFs launch new partnership - Cold Spring Harbor Laboratory
(CNCR) Long Term Investment Analysis - Stock Traders Daily
Trackinsight ETF data from 11th to 15th November, 2024 - ETF Express
The Best Biotech Stocks to Buy - Morningstar
Charted: Cancer Survival Rates Over Time - Visual Capitalist
Range Cancer Therapeutics - TBR News Media
How this award-winning TV host is setting the stage to help protect her health - TBR News Media
Investment fund pledges revenues in cancer research partnership with CSHL - TBR News Media
(CNCR) Trading Signals - Stock Traders Daily
At a Glance: Nov. 6 - Crain's New York Business
The 5 Best Biotech ETFs of 2024 - TradingView
Seagen’s Ex-CEO Starts Company to Develop Drug Tackling Wide Range of Cancers - BNN Bloomberg
Canadian Alternatives to Popular U.S. ETFs: How to Invest in SPY, QQQ, and More - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology - Yahoo Finance
(CNCR) Investment Report - Stock Traders Daily
How are ADC drug partnerships changing China’s biotech landscape? - Invesco
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV - Yahoo Finance
4 Solid ETFs Under $20 for Your Portfolio - Yahoo Finance
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market - Seeking Alpha
Range Cancer Therapeutics Etf Azioni (CNCR) Dati Finanziari
Non sono disponibili dati finanziari per Range Cancer Therapeutics Etf (CNCR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):